The Pill That Calms Your Skin by Silencing a Receptor Nobody Could Drug
Septerna just posted Phase 1 data proving it can block MRGPRX2, a mast cell receptor nobody could drug before. If the bet pays off, it could reshape how we treat chronic hives for millions of patients failed by antihistamines.
Imagine having hives that never go away. Not for a day, not for a week, but for months or even years. Your skin erupts in angry, itchy welts with no clear trigger, and the drugs your doctor prescribes barely take the edge off.
That's life with chronic spontaneous urticaria (CSU), a condition affecting millions of people worldwide. And for roughly half of them, the standard treatments simply don't work well enough. Antihistamines fail. Even the big-gun biologic, omalizumab (an injectable antibody that blocks IgE), leaves many patients still scratching.
Septerna thinks it found a new way in. And the first human data suggest the company might be right.
A Back Door Into the Mast Cell
To understand why Septerna's approach matters, you need to know a little about what causes hives in the first place.
CSU is driven by mast cells, the immune system's alarm bells. When mast cells activate, they dump histamine and other inflammatory chemicals into surrounding tissue. That's what creates the swelling, redness, and itch. Most treatments try to block the fallout: antihistamines mop up histamine after it's released, while omalizumab blocks IgE, one of the signals that triggers mast cells to degranulate (science-speak for "explode their contents").
But mast cells have more than one trigger. Think of them like a house with a front door and a back door. IgE is the front door, and it's the one most drugs target. The back door? That's a receptor called MRGPRX2.
MRGPRX2 activates mast cells through an entirely separate pathway, one that doesn't involve IgE at all. Neuropeptides from sensory nerves, defense peptides from skin cells, and other signals can all knock on this back door. When they do, the mast cell degranulates just the same, releasing a cocktail of inflammatory mediators that drive hives, itch, and swelling. This is why so many CSU patients don't respond to antihistamines or omalizumab: their mast cells are being activated through a door those drugs don't even touch.
Until now, nobody had a drug that could lock that back door. MRGPRX2 belongs to a massive family of receptors called GPCRs (G protein-coupled receptors), which are the targets of about a third of all FDA-approved drugs. But most of the 800 GPCRs in the human genome remain "undruggable" because scientists couldn't isolate them well enough to screen for drug candidates.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That's where Septerna's technology comes in.
The Nobel Prize Connection
Septerna wasn't born in a boardroom. It grew out of a lab belonging to Robert Lefkowitz, the Duke University scientist who won the 2012 Nobel Prize in Chemistry for his work on GPCRs. Together with collaborators Patrick Sexton and Arthur Christopoulos at Australia's Monash University, Lefkowitz's team developed a way to purify GPCRs in their natural functional state outside of cells.
The company calls it the Native Complex Platform, and it essentially lets researchers screen billions of compounds against receptors that were previously impossible to drug. Septerna launched in 2022 with $100 million in Series A funding led by Third Rock Ventures, with CEO Jeffrey Finer (a former Third Rock partner) at the helm. The company's name is a nerdy tribute to its roots: "sept" for the seven times GPCRs span the cell membrane, and "terna" for the ternary complex model Lefkowitz developed decades ago.
SEP-631, the company's lead drug for CSU, is an oral small molecule that acts as a negative allosteric modulator of MRGPRX2. In plain English: it doesn't block the receptor's main binding site directly. Instead, it changes the receptor's shape so that even when activating signals show up, the receptor can't fire properly. Think of it like loosening the strings on a guitar; you can still strum, but you won't get a note.
What the Phase 1 Data Actually Showed
Septerna ran a randomized, double-blind, placebo-controlled Phase 1 trial in healthy volunteers. The goal wasn't to treat CSU patients yet; it was to prove that SEP-631 could actually shut down MRGPRX2-driven mast cell activation in living humans.
To test this, researchers injected a substance called icatibant under the skin, which triggers mast cells through the MRGPRX2 pathway and causes a wheal (a raised, red bump, basically a controlled hive). They then measured how well SEP-631 prevented that wheal from forming, using short-wave infrared imaging for precise measurements.
The results were strikingly clean. At a lower icatibant challenge dose (10 µg/mL), SEP-631 achieved complete inhibition of wheal formation at doses as low as 10 mg once daily. When researchers cranked up the challenge tenfold (100 µg/mL), the drug still delivered near-complete inhibition at 90 and 200 mg once daily. That dose-dependent response is exactly what you want to see: more drug, more effect, in a predictable pattern.
On safety, the drug looked remarkably benign. Adverse events were comparable to placebo, with no severe or serious events reported. No worrisome lab abnormalities. No heart rhythm issues on ECG.
And the pharmacokinetics were convenient, too. SEP-631 has a half-life of roughly 24 hours, meaning one pill per day should do the job. Food didn't meaningfully affect absorption, so patients wouldn't need to plan their meals around their medication.
For a Phase 1 trial, this is about as good as it gets. Clean dose-response. Clean safety. Clean pharmacokinetics. The trifecta.
A $2.7 Billion Market With a Gaping Hole
The CSU treatment market is worth an estimated $2.7 billion globally in 2025, and it's growing at roughly 10% per year. That growth is being fueled by better diagnosis rates, increased awareness, and the arrival of new biologics and targeted therapies.
But the market's growth also reflects its biggest problem: existing treatments leave too many patients undertreated. Antihistamines are cheap and widely available, but they're insufficient for a huge chunk of patients, even at higher-than-standard doses. Omalizumab works better for refractory cases, but it's an injection, it's expensive, and it still doesn't help everyone. About half of CSU patients remain symptomatic despite available therapies.
An oral pill that attacks the disease through a completely different biological pathway? That's the kind of thing that could reshape treatment algorithms. Especially one that's convenient (once daily, no food restrictions) and appears well-tolerated.
Septerna plans to move SEP-631 into a Phase 2b trial in CSU in the second half of 2026, targeting adults with moderate-to-severe disease who are still symptomatic on antihistamines. That's the trial that will answer the real question: does shutting down MRGPRX2 actually make hives go away in sick patients?
Not Alone, But Way Ahead
Septerna isn't the only company interested in MRGPRX2. Arcus Biosciences has disclosed an oral MRGPRX2 antagonist program targeting atopic dermatitis and chronic urticaria, though it appears to be earlier in development based on its Q4 2025 pipeline update. Beyond Arcus, no other company has a disclosed clinical-stage MRGPRX2 program.
That first-mover advantage matters. Septerna now has human proof-of-concept data showing the mechanism works, which gives it a significant head start in the race to validate this target. If the Phase 2b data in actual CSU patients confirm what the Phase 1 wheal study suggests, the company could be sitting on a genuinely differentiated asset in a crowded but unsatisfied market.
It's worth noting that other companies are attacking CSU through different novel mechanisms. Novartis has remibrutinib, a BTK inhibitor, in late-stage development with approvals expected outside the U.S. in 2026. Sanofi is pushing rilzabrutinib through Phase 2/3 trials. But these drugs modulate mast cells indirectly; they don't target MRGPRX2 specifically.
Septerna is playing a different game. And so far, nobody else is on the same field.
The Road From Here
The company isn't limiting SEP-631 to hives, either. Septerna is evaluating the drug in additional mast cell-driven conditions including atopic dermatitis, interstitial cystitis, migraine, and asthma. If MRGPRX2 modulation proves broadly useful across these indications, SEP-631 could become a platform drug rather than a one-indication asset.
But let's not get ahead of ourselves. Phase 1 data in healthy volunteers, however clean, is just the opening act. The Phase 2b trial in actual CSU patients will be the real test. Can blocking MRGPRX2 reduce hive frequency, intensity, and itch in people who've failed other therapies? That's the billion-dollar question.
The biology makes a compelling case. The Phase 1 data provide proof that SEP-631 does what it's supposed to do in humans. And the unmet need is real; millions of people are living with a condition that their current medications can't adequately control.
Septerna has essentially proved that you can lock the back door. Now they need to show that locking it makes the house quieter.
Clinical & Regulatory4 min read
A Cold Virus Wants to Treat Your Colon Cancer
Oncolytics Biotech is betting that a modified cold virus can crack the toughest problem in colorectal cancer: the 95% of patients that immunotherapy can't help. Early data looks wild, and a new randomized trial just launched to prove it.
